PREVIOUS ISSUE
February 2018 Default Cover Image
Put to the testI have an idea. The idea is based upon what seems to be an almost-universally accepted belief that before there should be widespread use of surgical or medical therapies to treat patients with diseases, those therapies should first be vetted in controlled clinical trials involving a limited sample of the afflicted population.
Novel glaucoma drugs close at handA review of glaucoma drugs in various clinical study phases reveals that at least seven new glaucoma drugs were in trials and two others were approved by the FDA in 2017. Many drugs that have progressed the most act on prostaglandin receptors, though some combine this with other mechanisms of action.
SLT valuable tool in individualized approach for glaucoma managementWhen customizing treatment plans for glaucoma patients, selective laser trabeculoplasty (SLT) can be as useful in diagnosis as it is in reducing IOP, explains Inder Paul Singh, MD, FEBOphth.
Identifying glaucoma-related visual function lossA portable device for detecting multifocal steady-state visual evoked potentials associated with visual field stimulation is being developed as an objective test for identifying glaucoma-related visual function loss.
Neuropathic dry eye: When serum defeats tearsOphthalmology Times is pleased to announce Melina I. Morkin, MD, and Pedram Hamrah, MD, FACS, of New England Eye Center/Tufts Medical Center, Department of Ophthalmology, Tufts University School of Medicine, Boston, as the third-place winner of the 2017 Resident Writer’s Award Program, sponsored by Allergan. Their entry is featured here.
PREVIOUS ISSUE